Ibex
Ibex is revolutionizing cancer diagnostics with its AI imaging solution
About the company
Situation: The current process for cancer diagnosis, relying on a biopsy reviewed by a pathologist — compounded by a shortage of new pathologists — features 5-15% human error rates and prolonged waiting periods of weeks.
Solution: Ibex introduces a ground breaking AI-enhanced platform that automates biopsy reviews, ensuring a 99% accuracy rate and cutting diagnostic wait times in half, ushering in a new era of precise and efficient cancer diagnosis.
Market: Focused initially on the European and North American markets with 3,500 labs, Ibex targets a Specific Addressable Market of $5.2 billion ARR; expanding globally to reach 10,000 labs could elevate the Total Addressable Market to $12 billion ARR.
